Studies show that the shingles vaccine reduces the risk of developing shingles by approximately 51% in individuals aged 60+. It also reduces the severity and post-infection pain (postherpetic neuralgia) by about 67%.

Benefits of the Shingles Vaccine

• Reduces shingles risk by ~51% in those aged 60+.

• Reduces severity and post-shingles pain by ~67%.

Who Should Receive the Shingles Vaccine?

• Adults >60 years old, regardless of prior chickenpox history.

• Adults aged 50–59 years with a history of recurrent shingles or prior chickenpox.

Administration Method

• Single dose administered subcutaneously (under the skin).

Contraindications

• Allergy to vaccine components (e.g., gelatin, neomycin).

• Severe immunodeficiency.

• Acute illness (e.g., high fever, active infection)—delay vaccination until recovery.

• Pregnancy.